

22-25 JANUARY 2018 | HYATT REGENCY, MIAMI

Phacilitate

CELL & GENE THERAPY WORLD

THE WORLD'S NUMBER 1 PARTNERING EVENT
FOR ADVANCED THERAPIES

SUPER
EARLY BIRD
ENDS
OCTOBER 20!

Also part of the Phacilitate Leaders Forum



Phacilitate

IMMUNO-ONCOLOGY FRONTIERS WORLD



1200+
Attendees



400+
Organisations



200+
Speakers



30+
Countries

MEET THE SPEAKERS!



Dr Pascal Touchon
Senior Vice President, Global
Head Strategy BD&L;
Executive Board Member
Novartis Oncology



Dr Tim Anderson
Senior Analyst
Sanford C. Bernstein



Katherine A. High, MD,
President and Chief
Scientific Officer
Spark Therapeutics



Maria T. Millan, MD,
Interim President & CEO
**California Institute for Regenerative
Medicine (CIRM)**



Naomi Aronson, PhD,
Executive Director of Clinical
Evaluation, Innovation and Policy
in the Office of Clinical Affairs
**Blue Cross and Blue Shield
Association**



Timothy Moore
Executive Vice President of
Technical Operations
Kite Pharma



Dr Richard Jude Samulski
Scientific Founder, CSO & Executive Chairman
**Bamboo Therapeutics, Inc., a wholly
owned subsidiary of Pfizer Inc.**



Dr Evren Alici
CEO, **Vycellix**; Director, Cell &
Gene Therapy Centre
Karolinska Institutet




Kapil Bharti, PhD
Stadtman Investigator, Unit on
Ocular Stem Cell & Translational
Research (OSCTR)
National Eye Institute, NIH

Platinum sponsor

ThermoFisher
SCIENTIFIC

Find out more at www.cellandgenetherapyworld.com



“DYNAMIC,
INTERESTING AND
HIGHLY INTERACTIVE
EVENT THAT PROMOTES
EXCHANGE AND
NETWORKING IN A
HIGHLY SPECIALIZED
FIELD OF GENE
THERAPY.”

Nathalie Clement, Associate Director, Powell Gene
Therapy Center, University of Florida

“PHACILITATE IS A
MUST HAVE EVENT ON
MY CALENDAR”

Robert Deans, CTO, BlueRock Therapeutics



THE WORLD'S LARGEST AND MOST INFLUENTIAL MEETING FOR CELL & GENE THERAPY



PHACILITATE LEADERS FORUM MIAMI

The biggest and most influential meeting for Advanced Therapies in the world. Meet more decision makers in 4 days than you can in 4 months, from themed cocktail receptions on the banks of the Miami Canals to the already-legendary Phacilitate Miami Yacht Party, we set a brand new standard for informal networking and partnering.



2 EVENTS FOR THE PRICE OF 1

The only event to bring together the full ecosystem and KOLs from across cell, gene and immunotherapy. Phacilitate will bring together BOTH industry and scientific leaders to speed the commercialization of advanced therapies.



BE PART OF THE LARGEST SHOWCASE OF GROUND-BREAKING SOLUTIONS!

Phacilitate Leaders Forum Miami delivers the largest, most interactive exhibition featuring the most innovative solution providers with the tools that you need



WE DON'T JUST DELIVER THE ULTIMATE DECISION MAKERS...

Phacilitate fully recognizes the importance of more 'hands-on', technically-minded personnel through the provision of customized content, ranging from Phacilitate Training to our Hubs

“ A GREAT WAY TO EXPAND NETWORK WITH GLOBAL EXPERTS IN CELL AND GENE THERAPY WHO ARE FACING SIMILAR CHALLENGES. ”

STEVEN GOODMAN, DIRECTOR, STRATEGY AND ENGAGEMENT, GSK



INFLUENTIAL GLOBAL MEETING FOR ADVANCED THERAPIES

Phacilitate Cell & Gene Therapy World is the biggest and most influential global meeting for Advanced Therapies. **Meet more decision makers in 4 days than you usually can in 4 months!** 1,200+ attendees, 200+ speakers, 100+ exhibitors – it is the one meeting on the global calendar attended by all of the critical decision-makers from both inside and outside of the cell & gene therapy industry.



LARGEST, MOST IMMERSIVE TECHNOLOGY SHOWCASE IN THE INDUSTRY!

The world's largest, most immersive expo for cell & gene therapy. Phacilitate Leaders Forum Miami delivers the largest dedicated cell & gene therapy exhibition featuring the most innovative solution providers. Experience a unique blend of live show floor content and interactive journeys through our hubs, entertainment and networking of the highest quality.

FUN, EFFECTIVE NETWORKING

Setting a brand new standard for networking. From themed cocktail receptions on the banks of the Miami Canals, our Japan Partnering Lunch or our already-legendary Phacilitate Miami Yacht Party, Phacilitate Leaders Forum 2018 will support your partnering activities like never before.

GENUINE MUST ATTEND



Independent research from AMR International scored the event 4.5/5 - join 'the world's leading partnering event'

“Rated Excellent”

PRICELESS STRATEGIC & TACTICAL BUSINESS INSIGHT

Stay ahead of the game. Understand successful business and commercialization models. Identify future technologies and trends. Capitalize on opportunities!

AN EXPERT PANEL OF SPEAKERS

Sybil Danby, Director of Business Development, **Paragon**

Marlin Frechette, Director, Regulatory Affairs/Quality Systems, Management Representative, **Irvine Scientific**

Jessie H.-T. Ni, Ph.D., Chief Scientific Officer, **Irvine Scientific**

Dorit Harati, Vice President, Quality Assurance, Manufacturing & Logistics, **Gamida Cell**

Robert A. Preti, PhD, Chief Executive Officer and President, **PCT**

Sanjin Zvonic, PhD, Senior Director, Business Leader, Clinical and Commercial Manufacturing, **PCT**

Akshay Peer, PhD, VP of Sales & Account Management, **TrakCel**

Benjamin Le Quéré, Ph.D., Business Director, Bioprocess Solutions, **Saint-Gobain**

Ziv Sandalon, Associate Director of Innovation & Translation, **ABL, inc**

Dr. Suyash Prasad, Chief Medical Officer and Senior Vice President, **Audentes Therapeutics**

Dr Evren Alici, CEO, **Vyellix**; Director, Cell & Gene Therapy Centre, **Karolinska Institutet**

Biren Amin, Managing Director & Senior Equity Research Analyst, Biotechnology, **Jefferies LLC**

Dr Tim Anderson, Senior Analyst, **Sanford C. Bernstein**

Naomi Aronson, PhD, Executive Director of Clinical Evaluation, Innovation and Policy in the Office of Clinical Affairs, **Blue Cross and Blue Shield Association**

Dr Mark L. Bagarazzi, CMO, **Inovio Pharmaceuticals**

Dr John Beadle, CEO, **PsiOxus**

Kapil Bharti, PhD, Stadtman Investigator, Unit on Ocular Stem Cell & Translational Research (OSCTR), **National Eye Institute, NIH**

Greg Bonfiglio, Founder & Managing Partner, **Proteus, LLC**

Larry A. Couture, PhD, Chief Executive Officer, **Orbsen Therapeutics, Ltd**

Olivier Danos, PhD, Chief Scientific Officer, **REGENXBIO Inc.**

Dr Anthony Davies, President, **Dark Horse Consulting**

Dr Nicole Faust, Chief Scientific Officer, **CEVEC Pharmaceuticals**

Ed Field, President, brtxDISC™ Division, **BioRestorative Therapies**

Timothy C. Fong, PhD, MBA, Vice President, Science & Technology, **AlICells**

Professor Miguel Forte, Chief Medical Officer, **Bone Therapeutics**; Managing Director, **mC4Tx** (modified Cell for Therapeutics); Chief Commercialisation Officer and Chair of Commercialisation Committee, **ISCT**

Anna Gilbert, Director, Quality Assurance, **Nohla Therapeutics, Inc**

Aniz Girach, MD, Chief Medical Officer, **NightstaRx**

Richard Grant, Global Vice President, Cell Therapy, **Invetech**

Dr Christine Guenther, CEO & Medical Director, **apceth Biopharma GmbH**

Jon C. Gunther, PhD, Associate Director, Technical R&D, **Juno Therapeutics**

Patrick J. Hanley, PhD, Laboratory Facility Director, Cellular Therapy and Stem Cell Processing, Assistant Professor of Pediatrics, Children's National Health System, **The George Washington University**

Brian Hanrahan, Program Manager, Cell Therapy, **Invetech**

Katherine A. High, MD, President and Chief Scientific Officer, **Spark Therapeutics**

Cade Hildreth, MS, DMD, President & CEO, **BiolInformant.com**

Dr Bent Jakobsen, CSO, **Immunocore**

Haiyan Jiang, PhD, Vice President, Preclinical Science, **Editas Medicine**

Karl K. Johe, PhD, Founder & Chief Scientific Officer, **Neuralstem, Inc**

Louis Juliano, Senior Vice President, Global Sales & Business Development, **HemaCare Corporation**

Dr Sven Kili, Vice President & Head of Cell & Gene Therapy Development, Rare Disease Unit, **GlaxoSmithKline**

David Kirn, MD, co-Founder, Chairman & CEO, **4D Molecular Therapeutics** (provisionally confirmed)

Thomas R. Kreil, PhD, Associate Professor of Virology, Head of Pathogen Safety, **Shire**

Dr Klaus Kühlcke, Managing Director, **EUFETS GmbH**

Dr Joanne Kurtzberg, Director, **Carolinas Cord Blood Bank At Duke University**; President, **Cord Blood Association**

Dr Brian Lee, President and Co-Founder, **PBS Biotech**

Dr Yijia Li, Director, Shunxi Regenerative Medicine, **Yunnan Province Stem Cell Bank**

Dr Sheng Lin-Gibson, Leader, Biomaterials Group and Director, Regenerative Medicine Programs, **NIST**

Chris Mason, MD, PhD, CSO, **AvroBio**

Dr Michael May, President & CEO, **Centre for Commercialization of Regenerative Medicine (CCRM)**

Maria T. Millan, MD, Interim President & CEO, **California Institute for Regenerative Medicine (CIRM)**

Dr Jeffrey Miller, Deputy Director of the Masonic Cancer Center, **University of Minnesota**

Timothy J. Miller, PhD, President & CEO, **Abeona Therapeutics**

Timothy Moore, Executive Vice President of Technical Operations, **Kite Pharma**

Dr Shashi Murthy, Professor, **Northeastern University**

Scott Ohanesian, Senior Vice President of Commercial Operations, Clinical Trial Logistics, **QuickSTAT, A Quick Company**

Peter Olagunju, Senior Director, Technical Operations, **bluebird bio**

Dr Biju Parekkadan, Associate Professor, Bioengineering, **Rutgers University**; co-Founder, **Sentien Biotechnologies, Inc**

Dr Laszlo Radvanyi, Senior Vice President Head of ImmunoOncology Translational Innovation Platform, **EMD Serono**

Rodney Rietze, PhD, Technical Research & Development, Cell & Gene Therapy Unit, **Novartis Pharmaceutical Corporation**

Dr Isabelle Riviere, Director, Michael G. Harris Cell Therapy & Cell Engineering Facility, **Memorial Sloan Kettering Cancer Center**

Dr Richard Jude Samulski, Scientific Founder, CSO & Executive Chairman, **Bamboo Therapeutics, Inc.**, a wholly owned subsidiary of Pfizer Inc.

Dr Joshua Schimmer, Senior Managing Director, **Evercore ISI**

Dr Alaina Schlinker, Manager, Cell Therapy Application Support, **Fresenius Kabi**

Albert B. Seymour, PhD, Chief Scientific Officer, **Homology Medicines, Inc**

Dr Beth Shaz, Chief Medical & Scientific Officer, **New York Blood Center**

Richard O. Snyder, PhD, Chief Scientific Officer, **Brammer Bio**

Rizwana F. Sproule, PhD, Vice President, Regulatory Affairs, **Kite Pharma, Inc**

Dr David F. Stroncek, Chief, Cell Processing Section, Department of Transfusion Medicine, **NIH Clinical Center**

Dr Mark Throsby, CSO, **Merus**

Dr Pascal Touchon, Senior Vice President, Global Head Strategy BD&L; Executive Board Member, **Novartis Oncology**

Luk H. Vandenbergh, PhD, Director, Grousbeck Gene Therapy Center, Mass Eye and Ear, Assistant Professor, **Harvard Medical School**

Dr David Venables, CEO, **Synpromics**

Frances Verter, PhD, Founder & Director, **Parent's Guide to Cord Blood Foundation**

Dr Patricia Zilliox, Drug Development Officer, **Foundation Fighting Blindness**

Mark Zimmerman, PhD, Vice President, Strategy and Business Development, Interim Vice President of Operations, **ViaCyte**

Claudia Zylberberg, CEO, **Akron Biotech**

Dr Gopalan Narayanan, Vice President, **Disruptive Biologics**, **Voisin Consulting Life Sciences (VCLS)**

AGENDA AT-A-GLANCE

PRE-CONFERENCE DAY - MONDAY, JANUARY 22

Phacilitate Training

4 bespoke, half-day, CPD accredited training courses with sector-leading experts, giving you a vital edge in either partnering strategy or product development/manufacturing

- Cell & Gene Therapy Product Characterization - Quality by Design -
- Pharma Partnering Bootcamp - Partnering in Japan

DAY 1 - TUESDAY, JANUARY 23

Opening Morning Plenary: 2017, the year everything changed - what do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

Cell-based Therapy Track	Gene Therapy Vectors Track	Emerging Science Track: Immuno-oncology	Supply Chain Track: Raw & Starting Materials
Cost of Goods control	AAV, immunogenicity and re-dosing	Tumor microenvironment	Overcoming supply issues
Capacity (in-house vs. outsource)	Non-viral vectors	Cellular immunotherapy beyond CD19	Starting material optimization
Capacity (in-house vs. outsource)	Gene editing	Bispecific antibodies	Quality control and characterization of materials

DAY 2 - WEDNESDAY, JANUARY 24

Morning Plenary: Macro economic insights and innovative collaboration models to drive cell & gene therapy's ongoing maturation

Cell-based Therapy Track	Gene Therapy Vectors Track	Emerging Science Track: Stem Cell Therapy	Supply Chain Track: Data & Cold Chain Management	Cord Blood & Perinatal Stem Cells Track
Rationalizing cell therapy QC/QA for commercial scale	Viral & non-viral vector manufacturing capacity	MSCs and beyond	Data management and integration	Macro investor, pharma and regulatory trends
Scheduled Tour: Bioanalytics Hub	Bringing vector manufacturing processes from Phase I/II to commercial scale	Genetically modified stem cells	Scheduled Tour: Vein-to-Vein Supply Chain Hub	Evolving public & private bank business models
What product characterization tools do we need?	Current and emerging vector production platforms and characterization tools	Novel therapeutic areas and indications	Cold chain technologies and research	Evolving public & private bank business models

DAY 3 - THURSDAY, JANUARY 25


Morning Plenary: Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

Cord Blood & Perinatal Stem Cells Track: Clinical updates


Cell-based Therapy Track	Emerging Science Track: Gene Therapy for Rare Diseases	Clinical updates
Enabling decentralized manufacture	AAV gene therapy clinical updates	Cord blood expansion
Bioprocess toolbox of the future		

EXPERIENCE THE WORLD OF CELL & GENE T

SECOND FLOOR



WORLD'S LARGEST SHOWCASE CELL AND GENE THERAPY PIONEERS



JAPANESE PARTNERING LUNCH

This dedicated networking session delivers a unique opportunity to enable new partnerships and discussions with attendees from Japan



CORD BLOOD & PERINATAL STEM CELLS

Expanding on the success of last year's cord blood track, this year will feature a new and improved stream

SUPPLY CHAIN & LOGISTICS HUB

After 2017's successful launch, we and our partners are teaming up together to empower cell therapy developers to handle the complexities of a modern supply chain.



PHACILITATE TRAINING

Having an adequately skilled workforce has been identified as a major speed-bump to industrialisation, and as we see more practitioners join from adjacent sectors, you told us it was important to learn new and important skills.

Call us on +44 207 384 7993 to find out more about our CPD accredited training day!



TRANSLATION ACADEMY

Phacilitate and Cell and Gene Therapy Insights have teamed up to further support collaboration between academic and industry pioneers. The Translation Academy will highlight promising innovation and support its path to commercial success.

YACHT PARTY

Our legendary yacht party returns bigger and better than before for 2018! Tickets are limited and will be allocated on a first come, first served basis so don't miss out!



CO-LOCATION WITH IMMUNO-ONCOLOGY FRONTIERS WORLD

Collaborate with a community seeking to hone their I-O combination development strategies. Cell and Gene Therapy World and Immuno-Oncology Frontiers will be held side by side!



SPONSORS

Platinum sponsor

ThermoFisher
SCIENTIFIC

Gold Sponsors



Silver Sponsors



Bronze Sponsors




VENUE



HYATT REGENCY MIAMI

Indulge in the spirit of the city when you stay at this downtown Miami hotel. With its striking white towers overlooking the Miami River, Hyatt Regency Miami is a landmark hotel offering first rate service, expansive meeting space, and the most convenient location in the area. You'll enjoy easy access to popular attractions, like Brickell City Center, Wynwood Art District, Coral Gables, the Port of Miami, and the Latin flavor of Little Havana.

- Refreshed rooms with views: Enjoy gorgeous views of the river and bay in our refreshed guestrooms and suites with Hyatt Grand Beds and free Wi-Fi
- Close to many attractions: Unmatched location with easy access to an incredible selection of arts and entertainment
- Quintessential Miami dining experiences: Discover endless dining options for every meal with fresh, locally-sourced food at our hotel



Book your room online at cellandgenetherapyworld.com/about/venue and save with our exclusive delegate rate!

TOP 10 TOPICS AT CELL & GENE THERAPY WORLD 2018

21st Century Cures and the RMAT Designation; one year on, how has it been implemented?

Exploring monetization models for curative therapies: what are the viable models in payers' eyes today?

How to address questions and challenges around gene expression longevity/control, immunogenicity and re-dosing in *in vivo* gene therapy?

Beyond AML: What is being done to overcome solid tumor resistance to cellular immunotherapies?

Optimizing quality of raw and starting materials – what exactly constitutes 'good enough'?

Investor insights: How to safeguard against the threat of becoming technologically obsolete in today's 'next-gen' environment?

How to rationalize QC for commercial scale?

How to identify the data that is really critical to collect, and how to integrate and utilize it to the benefit of the overall supply chain?

What do ongoing public-private convergence and M&A trends, and the continuing development of hybrid business models, mean for the robustness of the Cord Blood banking sector globally?

How to truly enable decentralized manufacturing at commercial scale?

HOW TO REGISTER

Head to www.cellandgenetherapyworld.com to register now for our super early bird rates, saving you \$\$\$'s!

SUPER EARLY BIRD

Ends Friday 20th Oct

Delegate Type	Rates
Pharma/Biotech	\$2,595
Technology/Service Provider	\$3,995
Academic/Government/Not-for-Profit	\$1,195

EARLY BIRD

Ends Friday 1st Dec

Delegate Type	Rates
Pharma/Biotech	\$2,695
Technology/Service Provider	\$3,995
Academic/Government/Not-for-Profit	\$1,395

FULL RATE

Delegate Type	Rates
Pharma/Biotech	\$2,895
Technology/Service Provider	\$3,995
Academic/Government/Not-for-Profit	\$1,595

FOR INFORMATION ON:

Small company rates • Group discounts • 1-day attendance rate
Please email team@phacilitate.co.uk or call **+44 (0)20 7384 7993**